Market Cap 9.21B
Revenue (ttm) 1.16B
Net Income (ttm) 168.11M
EPS (ttm) N/A
PE Ratio 34.19
Forward PE 31.86
Profit Margin 14.50%
Debt to Equity Ratio 0.16
Volume 2,697,000
Avg Vol 2,272,600
Day's Range N/A - N/A
Shares Out 156.77M
Stochastic %K 93%
Beta 1.39
Analysts Strong Sell
Price Target $64.93

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors,...

Industry: Biotechnology
Sector: Healthcare
Phone: 612 379 8854
Fax: 612 656 4400
Address:
614 McKinley Place N.E., Minneapolis, United States
shitzushimazu
shitzushimazu Jul. 28 at 2:20 AM
$TECH turn up time?
0 · Reply
jtrader8000
jtrader8000 Jul. 25 at 5:46 AM
$TECH TECH - great ticker, good bounce off lows which isnt far away so very easy to manage downside from here, has been on big runs before 2022 highs, so hopefully this is the start of another run
0 · Reply
Fizz26
Fizz26 Jul. 24 at 11:16 PM
$DJIA $TECH great balance sheet and undervalued
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 3:15 PM
Scotiabank updates rating for Bio-Techne ( $TECH ) to Sector Outperform, target set at 90 → 75.
0 · Reply
Investogainerresearch
Investogainerresearch Jul. 10 at 6:29 PM
$TECHM.NSE Fundamental View- $TECH Mahindra Ltd. (TECHM) – Fundamental Summary (As of July 2025): Tech Mahindra is a leading Indian IT services and consulting company under the Mahindra Group, specializing in digital transformation, telecom solutions, and enterprise technology services. The $COMPANY has a strong client base across telecom, BFSI, healthcare, and manufacturing sectors globally. In FY24–25, $TECHM witnessed muted revenue growth due to challenges in the telecom vertical and a delay in discretionary IT spending from clients. However, the company is focusing on margin improvement through operational efficiency and cost optimization. Its return ratios—ROE and ROCE—have come under slight pressure but remain stable at around 14–16%. $TECHM maintains a debt-free balance sheet with strong cash reserves, and regularly rewards shareholders via dividends and buybacks. With new leadership and a renewed focus on next-gen tech areas like AI, 5G, and cloud services, the $COMPANY is positioning itself for a turnaround. $TECHM offers long-term potential, though near-term performance may remain range-bound due to sectoral headwinds. Technical View- As seen on the daily chart, $TECH Mahindra has witnessed a decline for the past two sessions and is currently trading within the range of its 14-day and 55-day EMAs. Today, the $STOCK opened at ₹1617.30, made an intraday high of ₹1617.30, a low of ₹1590.10, and closed at ₹1600.10. The Parabolic SAR has shifted above the price candles, indicating short-term bearishness. MACD is also showing a weakening trend, and RSI stands around 40.91, reflecting fading momentum. The price is now testing the 100-day EMA zone as a support level. With Q1 results scheduled on 16th July, the $STOCK is seen sustaining near a strong support zone. Any dip around ₹1560—which also aligns with its 200-day EMA—could be a good buying opportunity. With a stoploss of ₹1550, the $STOCK may potentially retest its 14-day EMA and move toward ₹1690–1700 levels in the short term. Warning- https://investogainerresearch.com/disclaimer https://investogainerresearch.com/standarddisclouser https://investogainerresearch.com/investorcharter
0 · Reply
Fizz26
Fizz26 Jul. 10 at 3:12 PM
$DJIA $TECH let’s goooo
0 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 12:00 PM
TD Cowen has updated their rating for Bio-Techne ( $TECH ) to Buy with a price target of 65.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 8 at 2:35 PM
Bio-Techne ($TECH) cements its leadership in the booming $2.35B in situ hybridization market with 70,000+ RNAscope probes. While margins face pressure, their spatial biology edge and Leica partnership could be the catalyst needed to justify that premium valuation. When your tech becomes the gold standard, pricing power follows. https://www.prnewswire.com/news-releases/2-35-billion-by-2030-why-in-situ-hybridization-is-revolutionizing-molecular-diagnostics--marketsandmarkets-302499850.html
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 1:17 PM
$TECH's new partnership with USP — a significant milestone for gene therapy development? 🤔 Bio-Techne's deal to distribute USP's mAb and AAV standards could enhance quality and compliance in biotherapeutic development. With a favorable earnings yield and a history of surprises, TECH aims to support advancements despite recent declines. Discover the full impact on TECH's prospects 👉 https://www.zacks.com/commentary/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-body-405&ADID=SYND_STOCKTWITS_TWEET_2_2557506_BODY_405
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 11:50 AM
New partnership could be a game-changer for $TECH 🧬📈 TECH is teaming up with USP to advance mAb and gene therapy testing — aiming to streamline analytics and improve product quality. Find out what this means for the stock’s upside 👉 https://www.zacks.com/stock/news/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2557506_TEASER
0 · Reply
Latest News on TECH
Bio-Techne to Present at Investor Conferences

May 29, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne to Present at Investor Conferences


Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 10:38 AM EDT - 2 months ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript


BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

May 7, 2025, 6:30 AM EDT - 2 months ago

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM


BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

May 7, 2025, 6:30 AM EDT - 2 months ago

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS


Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 2:24 PM EST - 6 months ago

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript


Bio-Techne Declares Dividend

Feb 5, 2025, 6:30 AM EST - 6 months ago

Bio-Techne Declares Dividend


Bio-Techne Releases Second Quarter Fiscal 2025 Results

Feb 5, 2025, 6:30 AM EST - 6 months ago

Bio-Techne Releases Second Quarter Fiscal 2025 Results


Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

Feb 4, 2025, 7:00 AM EST - 6 months ago

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors


ScaleReady awards a G-Rex® Grant to Moonlight Bio

Dec 18, 2024, 7:00 AM EST - 7 months ago

ScaleReady awards a G-Rex® Grant to Moonlight Bio


BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Dec 10, 2024, 7:00 AM EST - 8 months ago

BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY


shitzushimazu
shitzushimazu Jul. 28 at 2:20 AM
$TECH turn up time?
0 · Reply
jtrader8000
jtrader8000 Jul. 25 at 5:46 AM
$TECH TECH - great ticker, good bounce off lows which isnt far away so very easy to manage downside from here, has been on big runs before 2022 highs, so hopefully this is the start of another run
0 · Reply
Fizz26
Fizz26 Jul. 24 at 11:16 PM
$DJIA $TECH great balance sheet and undervalued
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 3:15 PM
Scotiabank updates rating for Bio-Techne ( $TECH ) to Sector Outperform, target set at 90 → 75.
0 · Reply
Investogainerresearch
Investogainerresearch Jul. 10 at 6:29 PM
$TECHM.NSE Fundamental View- $TECH Mahindra Ltd. (TECHM) – Fundamental Summary (As of July 2025): Tech Mahindra is a leading Indian IT services and consulting company under the Mahindra Group, specializing in digital transformation, telecom solutions, and enterprise technology services. The $COMPANY has a strong client base across telecom, BFSI, healthcare, and manufacturing sectors globally. In FY24–25, $TECHM witnessed muted revenue growth due to challenges in the telecom vertical and a delay in discretionary IT spending from clients. However, the company is focusing on margin improvement through operational efficiency and cost optimization. Its return ratios—ROE and ROCE—have come under slight pressure but remain stable at around 14–16%. $TECHM maintains a debt-free balance sheet with strong cash reserves, and regularly rewards shareholders via dividends and buybacks. With new leadership and a renewed focus on next-gen tech areas like AI, 5G, and cloud services, the $COMPANY is positioning itself for a turnaround. $TECHM offers long-term potential, though near-term performance may remain range-bound due to sectoral headwinds. Technical View- As seen on the daily chart, $TECH Mahindra has witnessed a decline for the past two sessions and is currently trading within the range of its 14-day and 55-day EMAs. Today, the $STOCK opened at ₹1617.30, made an intraday high of ₹1617.30, a low of ₹1590.10, and closed at ₹1600.10. The Parabolic SAR has shifted above the price candles, indicating short-term bearishness. MACD is also showing a weakening trend, and RSI stands around 40.91, reflecting fading momentum. The price is now testing the 100-day EMA zone as a support level. With Q1 results scheduled on 16th July, the $STOCK is seen sustaining near a strong support zone. Any dip around ₹1560—which also aligns with its 200-day EMA—could be a good buying opportunity. With a stoploss of ₹1550, the $STOCK may potentially retest its 14-day EMA and move toward ₹1690–1700 levels in the short term. Warning- https://investogainerresearch.com/disclaimer https://investogainerresearch.com/standarddisclouser https://investogainerresearch.com/investorcharter
0 · Reply
Fizz26
Fizz26 Jul. 10 at 3:12 PM
$DJIA $TECH let’s goooo
0 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 12:00 PM
TD Cowen has updated their rating for Bio-Techne ( $TECH ) to Buy with a price target of 65.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 8 at 2:35 PM
Bio-Techne ($TECH) cements its leadership in the booming $2.35B in situ hybridization market with 70,000+ RNAscope probes. While margins face pressure, their spatial biology edge and Leica partnership could be the catalyst needed to justify that premium valuation. When your tech becomes the gold standard, pricing power follows. https://www.prnewswire.com/news-releases/2-35-billion-by-2030-why-in-situ-hybridization-is-revolutionizing-molecular-diagnostics--marketsandmarkets-302499850.html
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 1:17 PM
$TECH's new partnership with USP — a significant milestone for gene therapy development? 🤔 Bio-Techne's deal to distribute USP's mAb and AAV standards could enhance quality and compliance in biotherapeutic development. With a favorable earnings yield and a history of surprises, TECH aims to support advancements despite recent declines. Discover the full impact on TECH's prospects 👉 https://www.zacks.com/commentary/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-body-405&ADID=SYND_STOCKTWITS_TWEET_2_2557506_BODY_405
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 11:50 AM
New partnership could be a game-changer for $TECH 🧬📈 TECH is teaming up with USP to advance mAb and gene therapy testing — aiming to streamline analytics and improve product quality. Find out what this means for the stock’s upside 👉 https://www.zacks.com/stock/news/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2557506_TEASER
0 · Reply
Fizz26
Fizz26 Jun. 26 at 5:47 PM
$DJIA $TECH ! Go long
0 · Reply
shitzushimazu
shitzushimazu Jun. 25 at 11:34 PM
$TECH really disappointed techne
0 · Reply
DonCorleone77
DonCorleone77 Jun. 24 at 11:04 AM
$TECH Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy Bio-Techne announced a distribution agreement with the U.S. Pharmacopeia, or USP, that enables the company to sell USP monoclonal antibody and recombinant adeno-associated virus, or AAV, reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide. Maintaining consistent mAb quality is vital for their efficacy. Both USP mAbs and AAV reference standards provide stringent materials that can be used with Bio-Techne's analytical instruments, such as the MauriceFlex system.
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 12:30 PM
Baird has updated their rating for Bio-Techne ( $TECH ) to Outperform with a price target of 88.
0 · Reply
BallaclavaBoys
BallaclavaBoys Jun. 12 at 6:03 PM
$TECH Over bought
0 · Reply
shitzushimazu
shitzushimazu Jun. 12 at 5:47 PM
$TECH lets get up and out techne
0 · Reply
ZacksResearch
ZacksResearch May. 29 at 4:06 PM
$TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today? Click here to learn more: https://www.zacks.com/stock/news/2478718/is-bio-techne-stock-the-right-pick-for-your-portfolio-now?cid=sm-stocktwits-2-2478718-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478718_TEASER
0 · Reply
ZacksResearch
ZacksResearch May. 29 at 1:12 PM
$TECH down 38.1% over the past year — what's dragging it down? 📉 Despite high single-digit growth in GMP reagents and strategic acquisitions, Bio-Techne faces macroeconomic headwinds, including rising costs and global tariffs, affecting its margins. Understand the risks before investing in TECH 👉 https://www.zacks.com/commentary/2478718/is-bio-techne-stock-the-right-pick-for-your-portfolio-now?cid=sm-stocktwits-2-2478718-body&ADID=SYND_STOCKTWITS_TWEET_2_2478718_BODY
0 · Reply
stuntman9883
stuntman9883 May. 20 at 1:48 PM
$TECH https://youtu.be/6bliafouSEA?si=nnlho3ueDdXrON5o good financials
0 · Reply
if_at_first
if_at_first May. 14 at 7:13 PM
$TECH From 54 to 48 in three days. An 11% drop ... why?
0 · Reply
Estimize
Estimize May. 14 at 10:00 AM
Wall St is expecting 0.51 EPS for $TECH Q4 [Reporting 08/12 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 12 at 11:20 AM
$TECH Bio-Techne To Showcase Latest Spatial Biology And Cell And Gene Therapy Workflow Solutions At ASGCT 2025 Meeting
0 · Reply